Protalex is Drug Discovery in United States that focus on immune thrombocytopenia business. Founded in 1999. They cover business area such as Protalex Inc, biopharmaceutical drug, inflammatory disease, rheumatoid arthritis, immune thrombocytopenia, an immunomodulatory therapy, aspect, animal model, autoimmune disease, activity, cultured human immune cell, very low concentration.
1999
( 25 years old in 2024 )
Immune Thrombocytopenia
-
131 Columbia Turnpike
Suite 1
Florham Park, NJ 07932
United States
Private
Protalex Incbiopharmaceutical druginflammatory diseaserheumatoid arthritisimmune thrombocytopeniaan immunomodulatory therapyaspectanimal modelautoimmune diseaseactivitycultured human immune cellvery low concentration
* We use standard office opening hours in near Protalex's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Protalex is Drug Discovery business from United States that founded in 1999 (25 years old in 2024), Protalex business is focusing on Immune Thrombocytopenia.
Protalex headquarter office and corporate office address is located in 131 Columbia Turnpike Suite 1 Florham Park, NJ 07932 United States.
Protalex was founded in United States.
In 2024, Protalex is currently focus on immune thrombocytopenia sector.
Above is snippet of Google Trends for "immune thrombocytopenia" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Protalex, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
